Compare EPR & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPR | STVN |
|---|---|---|
| Founded | 1997 | 1949 |
| Country | United States | Italy |
| Employees | 54 | N/A |
| Industry | Real Estate Investment Trusts | Containers/Packaging |
| Sector | Real Estate | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.7B |
| IPO Year | N/A | 2021 |
| Metric | EPR | STVN |
|---|---|---|
| Price | $56.87 | $18.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 3 |
| Target Price | ★ $58.94 | $25.67 |
| AVG Volume (30 Days) | ★ 590.7K | 360.2K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.28% | 0.39% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.66 | $9.67 |
| Revenue Next Year | $8.60 | $9.99 |
| P/E Ratio | ★ $25.00 | $27.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $48.11 | $12.89 |
| 52 Week High | $62.08 | $28.00 |
| Indicator | EPR | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 48.08 | 67.76 |
| Support Level | $56.08 | $14.23 |
| Resistance Level | $57.12 | $19.05 |
| Average True Range (ATR) | 0.94 | 0.65 |
| MACD | -0.19 | -0.03 |
| Stochastic Oscillator | 15.51 | 73.68 |
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.